tiprankstipranks
Trending News
More News >
Sinopharm Group Co Class H (HK:1099)
:1099
Hong Kong Market

Sinopharm Group Co (1099) Income Statement

Compare
6 Followers

Sinopharm Group Co Income Statement

Last quarter (Q4 2024), Sinopharm Group Co's total revenue was ¥289.78B, an increase of 98.80% from the same quarter last year. In Q4, Sinopharm Group Co's net income was ¥3.35B. See Sinopharm Group Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 584.51B¥ 596.57B¥ 552.15B¥ 521.05B¥ 456.41B
Gross Profit
¥ 44.26B¥ 48.51B¥ 47.43B¥ 44.05B¥ 40.32B
Operating Expenses
¥ 28.07B¥ 28.30B¥ 24.23B¥ 22.61B¥ 20.54B
Depreciation and Amortization
¥ 2.36B¥ 4.43B¥ 4.17B¥ 3.92B¥ 3.60B
EBITDA
¥ 20.17B¥ 26.90B¥ 26.25B¥ 24.68B¥ 22.62B
Operating Income
¥ 16.19B¥ 20.21B¥ 20.60B¥ 19.71B¥ 17.76B
Other Income/Expenses
¥ -2.19B¥ -697.06M¥ -2.04B¥ -2.71B¥ -2.16B
Pretax Income
¥ 14.00B¥ 19.51B¥ 18.56B¥ 17.00B¥ 15.60B
Net Income
¥ 7.05B¥ 9.05B¥ 14.35B¥ 13.06B¥ 12.10B
Per Share Metrics
Basic EPS
¥ 2.26¥ 2.90¥ 4.60¥ 4.20¥ 3.89
Diluted EPS
¥ 2.26¥ 2.90¥ 4.60¥ 4.20¥ 3.89
Weighted Average Shares Outstanding
3.12B 3.12B 3.12B 3.11B 3.11B
Weighted Average Shares Outstanding (Diluted)
3.12B 3.12B 3.12B 3.11B 3.11B
Currency in CNY

Sinopharm Group Co Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis